A giant jejunal gastrointestinal stromal tumor misconceived as pancreatic cystic neoplasm: A case report

Kitti Wongta\textsuperscript{a}, Vorapat Tangsirapat\textsuperscript{a},* Vichack Chakrapan Na Ayudhya\textsuperscript{a}, Papot Charutrugalchai\textsuperscript{a}, Singha Sripreepchappattana\textsuperscript{a}, Kobkool Chakrapan Na Ayudhya\textsuperscript{a}, Rapol Poolsavatkitikool\textsuperscript{a}, Paiboon Sookpotarom\textsuperscript{a}, Paisarn Vejchapipat\textsuperscript{b}

\textsuperscript{a}Department of Surgery, Panyanathaphikkhu Chonprathan Medical Center, Sirnakharinwirot University, Nonthaburi, 11120, Thailand
\textsuperscript{b}Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand

**A R T I C L E I N F O**

Article history:
Received 7 May 2019
Received in revised form 30 May 2019
Accepted 12 June 2019
Available online 17 June 2019

Keywords:
GISTs
Pancreatic tumor
Jejunum
Case report

**A B S T R A C T**

**INTRODUCTION:** Gastrointestinal stromal tumors (GISTs), although not common in gastrointestinal (GI) tumors, constitute the most frequent mesenchymal tumors of the GI tract [1]. GISTs, most frequently arising from stomach, rarely occurred at the small intestine, particularly at jejunum [2]. They are usually small and develop ulceration that proceeds to GI bleeding. Interestingly, our patient had an unusual presentation with a very large tumor arose from the jejunum. Not only there was an absence of GI symptoms, but the tumor initially was misconceived as a cystic lesion of the pancreas.

This work is compliant with the SCARE checklist, and also, has been reported in line with the SCARE criteria [3].

1. Introduction

Gastrointestinal stromal tumors (GISTs) are considered as rare neoplasms in gastrointestinal (GI) tumors; however, they are the most common mesenchymal tumors of the GI tract [1]. GISTs, most frequently arising from stomach, rarely occurred at the small intestine, particularly at jejunum [2]. They are usually small and develop ulceration that proceeds to GI bleeding. Interestingly, our patient had an unusual presentation with a very large tumor arose from the jejunum. Not only there was an absence of GI symptoms, but the tumor initially was misconceived as a cystic lesion of the pancreas.

2. Case presentation

A 59-year-old female patient has encountered a problem of unexplained weight loss over 10 kg within 6 months. Except for a nonspecific abdominal pain, there were no other GI symptoms. Her vital signs were within normal limit. On examination, she was pale. It was astounding for the patient that there was a palpable fist-sized mass at left upper quadrant during the physical examination. The routine laboratory tests revealed hemoglobin of 9 g/dl, and other blood tests were unremarkable.Computed tomography (CT) scan demonstrated a heterogeneously enhancing solid-cystic mass measuring 10 cm in maximal diameter at the pancreatic body and tail (Fig. 1). The provisional diagnosis of pancreatic mucinous cystadenoma was made and the patient was scheduled for distal pancreatectomy, lymphadenectomy, and splenectomy. At the theatre, the exploration through a Chevron incision revealed that the tumor originating from the proximal jejunum just distal to the ligament of Treitz, in lieu of a tumor of the pancreas (Fig. 2). The tumor that was abutting the body and tail of pancreas, with meticulous handling, was dissected and removed. There was no spillage or rupture of the capsule while removing the tumor. End-to-end jejunojejunostomy completed

* Corresponding author at: Department of Surgery, Panyanathaphikkhu Chonprathan Medical Center, 222 Tiwanon Road, Pak Kret, Nonthaburi, 11120, Thailand.

E-mail addresses: u4207015@yahoo.com (K. Wongta), vorapatu@hotmail.com (V. Tangsirapat), cvichack@gmail.com (V. Chakrapan Na Ayudhya), papotja@yahoo.com (P. Charutrugalchai), ssripreepchappattana@hotmail.com (S. Sripreepchappattana), kobkool@g.swu.ac.th (K. Chakrapan Na Ayudhya), rapol2507@gmail.com (R. Poolsavatkitikool), sookpotarom@yahoo.com (P. Sookpotarom), paisarvm@gmail.com (P. Vejchapipat).

https://doi.org/10.1016/j.jscr.2019.06.023

© 2019 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Axial (A) and coronal (B) view of contrasted abdominal CT showed heterogeneously enhanced solid-cystic tumor (larger arrow) abutted onto a great vessel (smaller arrow).

Fig. 2. The jejunal GIST was bluntly dissected from pancreas (A and B). The tumor originating from proximal jejunum was soft, round shaped, and tan-grey colored (C). There was a large central necrosis and cavity on cut surface (D).

the operation. There was an absence of adjacent mesenteric lymphadenopathy. Gross specimen, measuring 9 × 8 × 6.5 cm, was a soft, round-shaped, tan-grey colored mass with an irregular surface. There was large central necrosis and cavity. With a sequential serial section on histologic examination, the tumor was contained in the small intestinal segment in which the intramural mass consisted of interlacing bundle of spindle cells and interlacing bundle formation (Fig. 2). Nuclear atypia was presented. However, nuclear mitosis was scarcely found (0–1 /high-power field) (Fig. 3). The tumor margins were free from tumor cells. In the immunohistochemical study, the tumor cells were positive for tyrosine-kinase protein (CD117) and transmembrane protein (DOG1) which was consistent with GISTs. Post-operatively, there was no complication. The patient uneventfully recovered and discharged on postoperative day 8. Due to the large-sized tumor which entails an increased risk of tumor recurrence, adjuvant therapy was initiated with imatinib mesylate.

The patient was symptom-free during follow up at one month, three months, and six months after surgery. The CT scan was
3. Discussion

GISTs constitute the most common mesenchymal tumor of the GI tract, although their incidence is very low compared with those of all other tumors arising from the GI tract, they are most frequently found at the stomach. Though the tumors originated from the intestine, they usually arise from the duodenum and rarely from the jejunum. Generally, patients with GISTs present with a symptom of GI bleeding as a primary complaint. In contrast, jejunal GISTs are usually asymptomatic. Likewise, our case presented only with nonspecific abdominal pain and unexplained weight loss. Perforation of the jejunal GISTs has been reported, in which all of them presented with acute abdominal pain and generalized peritonitis. Fortunately, in spite of a large tumor, the patient has not encountered an unfortunate event.

CT scan typically demonstrates GISTs as a heterogenous occupied lesion with high vascularity. The large tumor may have a central necrotic area and intratumor hemorrhage. However, the definite diagnosis usually derived from a concluding pathologic report. Interestingly, in the report of this case, the CT scan revealed an enhancing solid-cystic tumor obviously originated from the pancreatic body and its tail. In addition, there was no apparent plane of separation between the two structures. Consequently, they were construed as a tumor of the pancreas rather than others. The reasonable explanation for the provisional diagnosis of mucinous cystadenoma might be its proximity to the body and tail of pancreas and its large size causing the tumor to compress the adjacent organ.

There are several antibodies that express in GISTs. However, it seems that CD117, a marker of intestinal Cajal cells, and DOG1, primarily discovered on GISTs, are the antibodies of choice in the diagnosis of GISTs. Following the routine pathologic report, the patient’s specimens were positive for CD117 and DOG1 confirming the diagnosis of GISTs. Presently, surgical tumor removal is the only potentially curative therapy for patients with primarily resectable GISTs. A small-sized tumor with low mitotic activity indicates low-risk tumor, predicting more favorable prognosis. However, the presence of a large-sized tumor categorized this patient into a high-risk group. Since lymph node metastasis is rarely presented, and there was no mesenteric lymphadenopathy in this patient, lymphadenectomy was not necessary. Again, as being classified as a high-risk patient, implementation of adjuvant imatinib mesylate seems to help increase the survival rate in this population.

4. Conclusion

To our knowledge, there has been a report of the heterotopic pancreas that was misdiagnosed as GISTs. However, jejunal GISTs mimicking a tumor of the pancreas has not been yet reported. With an infrequent presentation of a very large tumor arose from jejunum, and mimicked a cystic tumor of the pancreas, it was difficult to initially diagnose a jejunal GIST in this case.

Consent

The patient has been informed prior to the conduction of this manuscript and informed consent has also been obtained. A copy of the written consent is available for review by the editor-in-chief of the journal on request.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Ethical approval

The consent form and information sheet used in the process of obtaining a consent were approved by IRB at our institution.

Funding

This work received no funding.

Author contribution

Kitti Wongta collected data and wrote manuscript. Vichack Chakrapan Na Ayudhya, Kobkool Chakrapan Na Ayudhya, Rapol Poolsavatkitikool, Papot Charutragulchai, and Singha Srtpreechapatana contributed to conceptualization. Paiboon Sookpotarom and Vorapatu Tungsirapat contributed to conceptualization, data curation, supervision and editing of the manuscript. Paisarn Vejchapipat finally edited this manuscript.
Conflict of interest statement
None.

Guarantor
Kitti Wongta, Vorapatu Tangsirapat, and Paiboon Sookpotarom

Research Registration Number
NA.

Acknowledgements
The authors are grateful to our institution review board for allowing us to review and report this patient. The patient has been informed prior to the conduction of this manuscript and informed consent has also been obtained from the patient.

References
[1] S. Misawa, M. Takeda, H. Sakamoto, Y. Kini, H. Ota, H. Takagi, Spontaneous rupture of a giant gastrointestinal stromal tumor of the jejunum: a case report and literature review, World J. Surg. Oncol. 12 (2014) 153.
[2] S. Ito, Y. Tsuchitani, Y. Kim, S. Hashimoto, Y. Miura, T. Uemura, A gastrointestinal stromal tumor of the jejunum presenting with an intratumoral abscess: a case report and a literature review, Int. J. Surg. Case Rep. 48 (2018) 65–68.
[3] R.A. Agha, M.R. Borrelli, R. Farwana, K. Koshy, A. Fowler, D.P. Orgill, SCARE Group, The SCARE 2018 statement: updating consensus Surgical Case Repor (SCARE) guidelines, Int. J. Surg. 60 (2018) 132–136.
[4] A.K. Dhull, V. Kaushal, R. Dhanekhara, R. Atri, H. Singh, N. Marwah, The inside mystery of jejunal gastrointestinal stromal tumor: a rare case report and review of the literature, Case Rep. Oncol. Med. 10 (2011) 1155.
[5] N. Memmi, G. Cipe, H. Bektasoglu, T. Toydemir, H. Kadioglu, S. Bozkurt, et al., Perforated gastrointestinal stromal tumor in the jejunum: a rare cause of acute abdomen, Oncol. Lett. 4 (2012) 1244–1246.
[6] W. Attaallah, Ş Coşkun, G. Özden, H. Mollamemişoğlu, C. Yeğen, Spontaneous rupture of extraluminal jejunal gastrointestinal stromal tumor causing acute abdomen and hemoperitoneum, Ulus. Cerrahi Derg. 31 (2015) 99–101.
[7] K. Sato, H. Tazawa, S. Fujisaki, S. Fukuhara, K. Imaoka, Y. Hirata, et al., Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: a case report, Int. J. Surg. Case Rep. 39 (2017) 288–292.
[8] M.A. Beltrán, R.A. Tapia, V.J. Cortés, C. Larraín, V. Koscina, M.P. Riosco, et al., Multiple primary gastrointestinal stromal tumors presenting in jejunum and ileum, Indian J. Surg. 75 (Suppl. 1) (2013) 227–229.
[9] J. Kišuk, J. Žižčuk, A. Kemono, K. Gúniška-Ustrumovicz, J. Zurawska, B. Kędra, Expression of CD117, DOG-1, and IGF-1R in gastrointestinal stromal tumours – an analysis of 70 cases from 2004 to 2010, Prz. Gastroenterol. 11 (2016) 115–122.
[10] D. Söüztek, S. Yanık, A.N. Aklıoka, A. Söüztek, Z.T. Özdemir, C.U. Avşar, M. Gündalı, B. Sahin, F. Doron, Diagnostic and prognostic roles of DOG1 and Ki-67, in GIST patients with localized or advanced/metastatic disease, Int. J. Clin. Exp. Med. 7 (2014) 1914–1922.
[11] M. Novelli, S. Rossi, M. Rodriguez-Justo, P. Taniere, B. Seddon, L. Toffolatti, et al., DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinalstromal tumours, Histopathology 57 (2010) 259–270.
[12] T.J. Wu, L.Y. Lee, C.N. Yeh, P.Y. Wu, T.C. Chao, T.L. Hwang, et al., Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate, BMC Gastroenterol. 6 (2006) 29.
[13] Y. Fong, D.G. Coit, J.M. Woodruff, M.F. Brennan, Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients, Ann. Surg. 217 (1993) 72–77.
[14] H. Joensuu, M. Eriksson, K. Sundby Hall, A. Reichardt, J.T. Hartmann, D. Pink, et al., Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial, J. Clin. Oncol. 34 (2016) 244–250.
[15] L. Tu, J. Xu, H. Cao, Retrospective clinical analysis of heterotopic pancreas misdiagnosed as gastrointestinal stromal tumors, Zhonghua Wei Chang Wai Ke Za Zhi 17 (2014) 348–351.

Open Access
This article is published Open Access at sciedirect.com. It is distributed under the JJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.